Table of Content - U.S. Liposomal Doxorubicin Market

Liposomal doxorubicin is a chemotherapy drug, which is administered intravenously to treat AIDS-related Kaposi's sarcoma, breast cancer, ovarian cancer, and other solid tumors. Doxorubicin acts by blocking an enzyme called topoisomerase 2 that cancer cells need in order to divide and grow. Liposomal delivery of doxorubicin HCL (Hydrochloride) improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. Some side effects of using Doxil or doxorubicin hydrochloride liposome include low blood counts, hand-to-foot syndrome (palmar-plantar erythrodysesthesia), mouth sores, infusion-related side effects: shortness of breath, facial swelling, headache, back pain, flushing, tightness in the chest and throat, and/or low blood pressure.

Market Dynamics

The increasing prevalence of cancer is expected to drive demand for liposomal doxorubicin for treatment of the disease and aid in growth of the U.S. liposomal doxorubicin market. For instance, according to the American Cancer Society, in 2017, cancer was the second most common cause of death in the U.S., and accounted for nearly one out of four deaths. Moreover, according to National Cancer Institute, in 2019, around 1.8 million people were diagnosed with cancer in the U.S., and around 276,480 women and 2,670 men were diagnosed with breast cancer.

Key features of the study:

This report provides in-depth analysis of the U.S. liposomal doxorubicin market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the U.S. liposomal doxorubicin market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
Key companies covered as a part of this study include Johnson & Johnson, Baxter International Inc., Sun Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The U.S. liposomal doxorubicin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. liposomal doxorubicin market

Detailed Segmentation:

U.S. Liposomal Doxorubicin Market, By Drug Type:
- Branded
- Generic
U.S. Liposomal Doxorubicin Market, By Cancer Type:
- Ovarian Cancer
  - AIDS-related Kaposi’s Sarcoma
  - Multiple Myeloma
  - Others
U.S. Liposomal Doxorubicin Market, By States:
- California
- Texas
- Florida
- New York
- Pennsylvania
- Illinois
- Ohio
- Georgia
- North Carolina
- Michigan
- New Jersey
- Virginia
- Washington
- Arizona
- Others
Company Profiles
- Johnson & Johnson*
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Baxter International Inc.
- Sun Pharmaceutical Industries Ltd.
- Reddy’s Laboratories, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Drug Type
  - Market Snapshot, By Cancer Type
  - Market Snapshot, By States
  - Market Opportunity Map
U.S. Liposomal Doxorubicin Market Insights
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Demand Analysis
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Pricing Analysis
- Competitive Snapshot
- Pipeline Analysis
- Major Distributors
- Reimbursement Scenario
- Epidemiology
- Alternative Treatments
- Liposomal Doxorubicin Import and Export
Global Liposomal Doxorubicin Market Overview
- Definition
- Impact Analysis
- Market Overview
- Regional Share
- S. & Global Market Comparison
U.S. Liposomal Doxorubicin Market - Impact of Coronavirus (Covid-19) Pandemic
- Impact on Supply Chain
- Impact on Demand
U.S. Liposomal Doxorubicin Market, By Drug Type, 2016 – 2027 (US$ Million)
- Introduction
  - Market Share Analysis, 2020 and 2027(%)
  - Y-o-Y Growth Analysis, 2017 – 2027
  - Segment Trends
- Branded
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million)
- Generic
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million)
U.S. Liposomal Doxorubicin Market, By Cancer Type, 2016 – 2027 (US$ Million)
- Introduction
  - Market Share Analysis, 2020 and 2027(%)
  - Y-o-Y Growth Analysis, 2017 – 2027
  - Segment Trends
- Ovarian Cancer
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million)
- AIDS-related Kaposi’s Sarcoma
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million
- Multiple Myeloma
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million)
U.S. Liposomal Doxorubicin Market, By States, 2016 – 2027 (US$ Million)
- Introduction
  - Market Share Analysis, 2020 and 2027(%)
  - Y-o-Y Growth Analysis, 2017 – 2027
  - Country at Trends
- California
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Texas
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Florida
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- New York
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Pennsylvania
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Illinois
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Ohio
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Georgia
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- North Carolina
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Michigan
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- New Jersey
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Virginia
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Washington
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Arizona
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
Company Profiles
- Johnson & Johnson
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Baxter International Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Sun Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Reddy’s Laboratories, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
Section
- Research Methodology
- About us
- Contacts

*Browse 9 market data tables and 29 figures on "liposomal doxorubicin market” – U.S. forecast to 2027

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

Table of Contents

Need a Custom Report?

EXISTING CLIENTELE